The neurotrophic keratitis treatment market size is projected to expand from USD 0.88 billion in 2025 and USD 0.92 billion in 2026 to USD 1.21 billion by 2031, registering a CAGR of 5.58% between 2026 to 2031. This report is Segmented by Therapy Type (Drugs-Artificial Tears, Recombinant Human Nerve Growth Factors Eye Drops, Antibiotics, Contact Lens), Disease Stage (Stage I, Stage II, Stage III), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).
Other drivers and restraints analyzed in the detailed report include:
Antibiotics remain ancillary, prescribed prophylactically when defects exceed 2 mm, but they occupy a small revenue slice. Gene therapies are poised to displace chronic eye-drop regimens; Krystal Biotech’s KB801 began dosing in July 2025 and uses a replication-defective HSV-1 vector to provide twice-weekly NGF expression, potentially redefining convenience standards. Should early data replicate cenegermin’s healing outcomes, payer calculus could shift quickly, reducing artificial-tear dependence and altering how the neurotrophic keratitis treatment market evaluates cost-benefit thresholds.
Europe lags North America in revenue yet benefits from an earlier EMA nod and Dompé’s Italian distribution center. Germany’s G-BA labeled cenegermin as conferring “additional benefit” yet is pressing for further rebates, and France imposes tight hospital caps on orphan-drug budgets. EU MDR 2017/745 has slowed U.S. device entry but spurred European tissue banks to scale, partly offsetting supply bottlenecks in amniotic membrane.
Asia-Pacific is forecast to grow fastest at a 5.71% CAGR, propelled by India’s surging diabetes load and China’s positive Phase IV rhNGF data that pave the way for NMPA clearance. Japan and South Korea await regulatory filings yet already perform neurotization with national insurance support, creating pent-up demand once rhNGF or gene therapy clears approval. Middle East and Africa remain constrained by testing gaps and reimbursement limits, whereas Brazil and Argentina show gradual uptake via private insurers.
Global Neurotrophic Keratitis Treatment Market Trends and Insights
Expanding Access to Cenegermin (rhNGF) as First Approved Therapy
Cenegermin’s real-world Phase IV data from China reported 84.6% epithelial closure at week 8, with 90.9% durability at week 56, validating efficacy beyond the pivotal trials. Post-exclusivity biosimilar pursuit is rapid, yet the two-to-eight-degree storage requirement and 15-day discard rule maintain a supply moat for manufacturers with specialty pharmacy infrastructure. Medicare Part D covers the USD 118,230 eight-week course, but prior authorization imposes 30-60-day delays, nudging hospitals to counsel patients aggressively on adherence. European payers negotiate country-specific rebates, and CADTH has demanded 95% price cuts, signaling cost-effectiveness friction. Gene therapies such as KB801 promise twice-weekly dosing, potentially collapsing both caregiver burden and cold-chain expense.Rising NK Risk Factors (HSV/HZO, Diabetes)
India hosts 101 million people with diabetes, a figure that could reach 134 million by 2045; diabetic keratopathy affects 47-64% of this population, feeding directly into neurotrophic keratitis prevalence. HSV and HZO continue to underpin neuropathic corneal damage worldwide, and HZO incidence doubles every decade after age 50. Collectively, 31.59% of neurotrophic keratitis patients now carry a diabetes comorbidity, correlating with worse visual outcomes and catalyzing demand for adjuncts like topical insulin, which achieved 81-90% healing in 2024-2025 trials. As LASIK volumes rebound, postoperative hypoesthesia could further enlarge the neurotrophic keratitis treatment market.High Cost and Cost-Effectiveness Headwinds for rhNGF Therapy
CADTH calculated an incremental cost-effectiveness ratio above CAD 1 million per QALY and advised reimbursement only after a 95% price cut. Germany’s G-BA conferred an “additional benefit” label but is pressing for discounts, while France enforces hospital budget ceilings. Outside wealthy payers, six-times-daily administration imposes hidden expenses because many elderly patients require caregiver assistance. Biosimilars may erode price, yet stringent cold-chain protocols and proprietary fill-finish capabilities remain barriers to commoditization.Other drivers and restraints analyzed in the detailed report include:
- Increased Diagnosis Via Esthesiometry and In Vivo Confocal Microscopy
- Wider Payer Recognition of Amniotic Membrane Devices
- Underdiagnosis and Late Presentation Due to Asymptomatic Onset
Segment Analysis
Artificial tears retained 45.82% of neurotrophic keratitis treatment market share in 2025. Their dominance stems from payer-driven step therapy that forces a 90-day trial before higher-cost biologics receive approval, a cycle that perpetuates volume within retail channels. The neurotrophic keratitis treatment market size tied to contact lens solutions is projected to climb at a 5.87% CAGR over 2026-2031 as BostonSight PROSE and EyePrint scleral devices migrate from salvage to first-line protection, establishing a fluid reservoir that shields damaged corneas while awaiting regenerative therapy authorization. Recombinant human nerve growth factor delivered USD 1 billion sales in 2024, yet its six-times-daily regimen and USD 118,230 price tag restrict broad uptake despite proven 84.6% closure rates in Chinese real-world data.Antibiotics remain ancillary, prescribed prophylactically when defects exceed 2 mm, but they occupy a small revenue slice. Gene therapies are poised to displace chronic eye-drop regimens; Krystal Biotech’s KB801 began dosing in July 2025 and uses a replication-defective HSV-1 vector to provide twice-weekly NGF expression, potentially redefining convenience standards. Should early data replicate cenegermin’s healing outcomes, payer calculus could shift quickly, reducing artificial-tear dependence and altering how the neurotrophic keratitis treatment market evaluates cost-benefit thresholds.
Complete Report Scope:
- By Therapy Type
- Drugs-Artificial Tears
- Recombinant Human Nerve Growth Factors Eye Drops
- Antibiotics
- Contact Lens
- By Disease Stage
- Stage I
- Stage II
- Stage III
- By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America commanded 38.95% of 2025 revenue in the neurotrophic keratitis treatment market, with Medicare Part D covering cenegermin despite 30-60-day prior authorization that elongates disease course. Canada’s CADTH approval is conditional on steep discounts, limiting provincial uptake outside Quebec and Ontario. Mexico’s private hospitals carry cenegermin for inbound medical tourists but domestic adoption stays muted due to out-of-pocket burden.Europe lags North America in revenue yet benefits from an earlier EMA nod and Dompé’s Italian distribution center. Germany’s G-BA labeled cenegermin as conferring “additional benefit” yet is pressing for further rebates, and France imposes tight hospital caps on orphan-drug budgets. EU MDR 2017/745 has slowed U.S. device entry but spurred European tissue banks to scale, partly offsetting supply bottlenecks in amniotic membrane.
Asia-Pacific is forecast to grow fastest at a 5.71% CAGR, propelled by India’s surging diabetes load and China’s positive Phase IV rhNGF data that pave the way for NMPA clearance. Japan and South Korea await regulatory filings yet already perform neurotization with national insurance support, creating pent-up demand once rhNGF or gene therapy clears approval. Middle East and Africa remain constrained by testing gaps and reimbursement limits, whereas Brazil and Argentina show gradual uptake via private insurers.
List of Companies Covered in this Report:
- AxoGen, Inc.
- Bausch + Lomb
- BioTissue, Inc.
- BostonSight
- BRIM Biotechnology, Inc.
- CooperVision Specialty EyeCare / Blanchard
- Dompe farmaceutici S.p.A.
- EyePrint Prosthetics
- Katena Products / IOP Ophthalmics
- Krystal Biotech, Inc.
- Laboratoires Thea
- Recordati Rare Diseases / MimeTech S.r.l.
- RegeneRx Biopharmaceuticals, Inc.
- SynergEyes, Inc.
- Visionary Optics
- Vital Tears
- X-Cel Specialty Contacts
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AxoGen, Inc.
- Bausch + Lomb
- BioTissue, Inc.
- BostonSight
- BRIM Biotechnology, Inc.
- CooperVision Specialty EyeCare / Blanchard
- Dompe farmaceutici S.p.A.
- EyePrint Prosthetics
- Katena Products / IOP Ophthalmics
- Krystal Biotech, Inc.
- Laboratoires Thea
- Recordati Rare Diseases / MimeTech S.r.l.
- RegeneRx Biopharmaceuticals, Inc.
- SynergEyes, Inc.
- Visionary Optics
- Vital Tears
- X-Cel Specialty Contacts
